Makino T, Yamasaki M, Tanaka K, Tatsumi M, Takiguchi S, Hatazawa J, et al. Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. Surgery. 2017;162(4):836–45.

Article  PubMed  Google Scholar 

Makino T, Yamasaki M, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, et al. Treatment and clinical outcome of clinical T4 esophageal cancer: a systematic review. Ann Gastroenterol Surg. 2018;3(2):169–80.

Article  PubMed  PubMed Central  Google Scholar 

Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81(3):684–90.

Article  CAS  PubMed  Google Scholar 

Huang TT, Li SH, Chen YH, Chen YH, Lu HI, Lo CM, et al. Definitive chemoradiotherapy for clinical T4b esophageal cancer - Treatment outcomes, failure patterns, and prognostic factors. Radiother Oncol. 2021;157:56–62.

Article  PubMed  Google Scholar 

Hamer PW, Hight SC, Ward IG, Harris DL, Woodham BL. Flint R Stricture rate after chemoradiotherapy and radiotherapy for oesophageal squamous cell carcinoma: a 20-year experience. ANZJ Surg. 2019;89(4):367–71.

Article  Google Scholar 

Matsubara T, Ueda M, Kokudo N, Takahashi T, Muto T. Yanagisawa a role of esophagectomy in treatment of esophageal carcinoma wit clinical evidence of adjacent organ invasion. World J Surg. 2001;25(3):279–84.

Article  CAS  PubMed  Google Scholar 

Yokota T, Kato K, Hamamoto Y, Tsubosa Y, Ogawa H, Ito Y, et al. A 3-Year Overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for locally advanced unresectable esophageal cancer. Ann Surg Oncol. 2020;27(2):460–7.

Article  PubMed  Google Scholar 

Miyata H, Sugimura K, Motoori M, Omori T, Yamamoto K, Yanagimoto Y, et al. Clinical implication of conversion surgery after induction therapy for T4b thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26(13):4737–43.

Article  PubMed  Google Scholar 

Ohkura Y, Ueno M, Udagawa H. Advantage factors of R0 curative conversion esophagectomy and the optimal extent of lymphadenectomy after induction therapy for cT4b thoracic esophageal cancer. Ann Gastroenterol Surg. 2020;5(2):204–14.

Article  PubMed  PubMed Central  Google Scholar 

Yamaguchi S, Morita M, Yamamoto M, Egashira A, Kawano H, Kinjo N, et al. Long-term outcom of definitive chemoradiotherapy and induction chemoradiotherapy followed by surgery for T4 esophageal cancer with tracheobronchial invation. Ann Surg Oncol. 2018;25(11):3280–7.

Article  PubMed  Google Scholar 

Pape M, Veen LM, Smit TM, Kuijper SC, Vissers PA, Geijsen ED, et al. Late toxicity and health-related quality of life following definitive chemoradiotherapy for esophageal cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2023;117(1):31–44.

Article  PubMed  Google Scholar 

Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1078–85.

Article  PubMed  PubMed Central  Google Scholar 

Chen B, Deng M, Yang C, Dragomir MP, Zhao L, Bai K, et al. High incidence of esophageal fistula on patients with clinical T4b esophageal squamous cell carcinoma who received chemoradiotherapy: a retrospectie analysis. Radiother Oncol. 2021;158:191–9.

Article  PubMed  Google Scholar 

Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501–P2). Int J Radiat Oncol Biol Phys. 2014;89(4):872–9.

Article  CAS  PubMed  Google Scholar 

Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota Y, et al. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 2016;78(1):91–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Xiao L, Wang S, Pang Q, Wang J. Addition of induction or consolidation chemotherapy in definitive concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for patients with unresectable esophageal cancer: a systematic review and meta-analysis. Front Oncol. 2021;11: 665231.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Habu T, Kumanishi R, Ogata T, Fujisawa T, Mishima S, Kotani D et al. Complete response to definitive chemotheradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma. Esophagus. 2023;20(3):533–540. Ann Gastroenterol Surg. 2020;5(2):204–214

Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, et al. First-line pembrolizumab+chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus. 2022;19(4):683–92.

Article  PubMed  PubMed Central  Google Scholar